Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Cipla's US sales are expected to be adversely impacted by price erosion and supply disruptions for tumor drug Lanreotide, ...

Stay informed with the Cipla Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

The Nifty breached the 23,000 mark intra-day for the first time since June 2024, closing at 23,025, down 320 points. The ...

Read here for an analysis of PayPal's potential for growth in 2025, supported by strong cash flow and margins, driving a buy ...

Cipla share price has risen by 10% over the past 12 months and 64% over the last three years. The company's current market ...

Stocks like L&T Finance, Sunteck Realty, Jammu and Kashmir Bank, Prakash Industries, Bank of Baroda, Torrent Power, Landmark ...

Cipla on Monday (January 20) announced that the United States Food and Drug Administration conducted an inspection of its ...

In a major win for Cipla Ltd., the National Pharmaceutical Pricing Authority (NPPA) has issued a revised calculation sheet ...

Highlights:32 out of 50 constituent stocks of Nifty50 ended in the red, dragged by Wipro, HDFC Bank, Tech Mahindra, Adani ...

Alibaba slashes Qwen-VL model prices by up to 85%, intensifying China's AI price war to gain market share. Qwen-VL interprets text and images; Alibaba focuses on enterprise AI rather than consumer ...